PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Coronavirus Crackdown: Judge Orders Canadian Church Locked to Prevent Sunday Worship Services

Show Me

Boeing fires dozens of employees for ‘racist’ behavior

Show Me

British public now trust Amazon more than the Royal Mail

Show Me

Sen. Manchin says he was ready to ‘stay and fight’ during Capitol riot

Show Me

EXC: A Top U.S. Teacher Training Org is Partnered With A Chinese Communist Group Promoting ‘Socialist’ Nursery Rhymes.

Show Me

Study Found Toxin from Genetically Modified Crops is Showing up in Human Blood

Show Me

May Day 1971: Daniel Ellsberg on Joining Noam Chomsky, Howard Zinn at Historic Antiwar Direct Action

Show Me

The False and Exaggerated Claims Still Being Spread About the Capitol Riot

Show Me

Is There a Case for Legalizing Heroin?

Show Me

CENSORED: Toensing, former Deputy Assistant Attorney General and diGenova, former U.S. Attorney & Special Counsel | Video: 9 Minutes 38 Seconds

Show Me

Are fully vaccinated liberals afraid to remove their masks because they’ll look like Republicans?

Show Me

Susan Wright advances to runoff in Texas special election

Show Me

Stone Says He Took ‘Not a Dime’ From Anyone Seeking Trump Pardon

Show Me

To be tracked or not? Apple Is now giving us the choice

Show Me

Doctors prescribe more opioids to COVID-19 ‘long haulers,’ raising addiction fears

Show Me

(READ) FBI releases Seth Rich-related documents | “The records appear to suggest that someone could have paid for his death.”

Show Me

Antifa Assaults Small Child, Seattle Police During May Day Riot, Say Cops

Show Me

BREAKING: Mitt Romney Booed At Utah GOP Convention, Tells Crowd ‘You Can Boo All You Want’

Show Me

Hacker Erases UNC Conservative Student Publication’s Website

Show Me

BLM-Antifa Rioters Target Upscale Restaurant in Louisville, Kentucky – Heroic Patrons Refuse to Bow Down, Tell Mob ‘Bring It On, Let’s Go!’

Show Me

Assault On The Ballot Box – Lessons Learned In Pennsylvania

Show Me

Iodine is Important but a New Study Shows Too Much Causes Problems

Show Me

Even Texas Has Communists

Show Me

Here Is What Republican Voters Really Believe in. It’s a Shame the GOP Has No Idea

Show Me

Dershowitz: FBI’s Raid of Giuliani ‘Unconstitutional’

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded May 1, 2021 | Video: 48 Minutes 18 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded May 1, 2021 | Video: 48 Minutes 35 Seconds

Show Me

Michael Collins, Apollo 11 Astronaut, Remembered By NASA | Video: 1 Minute 44 Seconds

Show Me

The Things We Don’t Know | “Buzz Aldrin Took Holy Communion on the Moon. NASA Kept it Quiet”

Show Me

How the Pentagon Started Taking U.F.O.s Seriously

Show Me

Why Is the Left Allowed to Be ‘Transphobic’ and Racist?

Show Me

Could Your Body Render Future COVID Vaccines Useless?

Show Me

The Time Has Come for Cannabis Equity

Show Me

Johnson & Johnson COVID vaccine returns next week and more Maryland doctors will offer vaccines

Show Me

100 Days from America First to America Last: GM Joins Ford and Moves Automotive Plant to Mexico to Escape Biden Taxes

Show Me

It’s Been 6 Months Since CNN Gave Zoom Masturbator Jeffrey Toobin ‘Time Off’ To Deal With a ‘Personal Issue’

Show Me

DNC Panelist Calls For The Destruction Of Capitalism

Show Me

Let’s Call BLM What It Is – Marxist

Show Me

After a year of digital hearings, Minnesota federal courts moving back to in-person operation

Show Me

Ashli Babbitt; Chip Crunch; Inside 60 Minutes at CBS

Show Me